The goal of our lab is to develop novel macrophage targeted therapies for the treatment of solid tumors with
Our lab has identified a novel macrophage autonomous pathway involving Rac2 and Syk kinase downstream of the provisional integrins, a4b1 and avb3 that controls immunosuppressive macrophage differentiation in tumor growth and metastasis. Our recent work has demonstrated Syk as a novel immuno-oncology target which plays a crucial role in the control of macrophage-mediated immune suppression and the inhibition of anti-tumor immunity in the lung carcinoma model. We have shown that genetic or pharmacologic inhibition of Syk and/or PI3Kgamma in macrophages promotes a proinﬂammatory macrophage phenotype, restores CD8+ T-cell activity, destabilizes HIF under hypoxia, and stimulates an antitumor immune response in various syngeneic mouse models.
Schematic representation of Syk, PI3K gamma, HIF1/2 alpha in the control of tumor immunosuppression.